Yakup Ergün/X
Mar 12, 2025, 08:20
Yakup Ergün: Postchemotherapy Retroperitoneal Lymph Node Dissection
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article by R.S. Matulewicz, et al. on LinkedIn:
“Postchemotherapy Retroperitoneal Lymph Node Dissection.
This study challenges the routine 1 cm residual mass cut-off in clinical practice, demonstrating that even with residual masses <1 cm, viable tumor (2%) and teratoma (22%) are detected.
Is it time to reconsider the RPLND criteria?”
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ cell tumors.
Authors: R.S. Matulewicz, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 12, 2025, 08:20
Mar 12, 2025, 08:18
Mar 12, 2025, 08:13
Mar 12, 2025, 07:36
Mar 12, 2025, 06:58
Mar 12, 2025, 06:49
Mar 12, 2025, 06:44